SCHEMBL5832054

SCHEMBL5832054

COc1cc(-c2nc3ccccc3o2)ccc1Cc1cccnc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.60
▸ TP53 P04637 2/20 0.55
▸ TSHR P16473 3/20 0.53
▸ HSD17B10 Q99714 5/20 0.52
▸ ALDH1A1 P00352 4/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ PDE10A Q9Y233 5/20 0.48
▸ HPGD P15428 4/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ GAA P10253 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ PTGS2 P35354 1/20 0.45
▸ P2RY14 Q15391 1/20 0.45
▸ PDK1 Q15118 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831945 0.88 NPC1 (0.64) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5832250 0.81 NPC1 (0.62) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5833322 0.80 NPC1 (0.65) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5832760 0.79 NPC1 (0.71) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5832858 0.79 NPC1 (0.67) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL660569 0.77 NPC1 (0.67) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL28436509 0.76 NPC1 (1.00) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5832162 0.76 NPC1 (0.59) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5832925 0.76 NPC1 (0.59) NPC1TP53TSHRHSD17B10ALDH1A1
SCHEMBL5832117 0.76 NPC1 (0.59) NPC1TP53HSD17B10ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 — — US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 — — EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 — — US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 — — EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 — — WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885TP53 4829/4885TSHR 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback